PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Benralizumab - Severe eosinophilic asthma
PAD Profile : Benralizumab - Severe eosinophilic asthma Important
Keywords :
severe allergic asthma
Brand Names Include :
Fasenra
Important Information :
Service not currently provided by any Surrey Heartlands Trusts
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
16 April 2018
Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Associated BNF Codes
03. Respiratory System
03.04.02. Allergen immunotherapy